Arexvy, a respiratory syncytial virus (RSV) vaccine, is a brand-name intramuscular injection. It’s prescribed to help prevent lower respiratory infections from RSV. Arexvy has no known ...

The sales for Arexvy were reported at approximately £709M ($865.98M), a figure that outpaced analysts' expectations which were pegged at £358M.

The Food and Drug Administration on Wednesday approved Arexvy, the world's first respiratory syncytial virus (RSV) vaccine — a scientific breakthrough 60 years in the making.

AREXVY was approved by the US Food and Drug Administration (FDA) on May 3rd, 2023, for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in ...

On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older.

In May, the U.K. company was first to secure FDA approval for its shot Arexvy for adults 60 and older, beating out rivals from Pfizer and Moderna.

The US FDA approved an RSV vaccine called Arexvy. How effective is it, when will it be available, and who can take it? CNN Medical Analyst Dr. Leana Wen explains.

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

Any decisions on the potential label expansion of Arexvy are expected in 2024. Another RSV vaccine, Pfizer’s Abrysvo, was also approved this year for use in people age 60 and older.

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified. See what to expect from GSK's Q3.